Algae Dynamics (OTCQB:ADYNF) signed a memorandum of understanding with licensed producer Bonify, in order to supply raw cannabis plant material for oil sale and research.
As quoted in the press release:
Bonify is a Licensed Producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada with the capability to grow multiple strains of cannabis in its state of the art 320,000 square foot facility. It is anticipated that this MOU will lead to definitive service and supply agreements to be negotiated in the near future.
Under the terms of the MOU, raw cannabis plant material will be shipped to ARA – Avanti Rx Analytics Inc. (“ARA”), a company with oil extraction capability with whom the Company has an agreement to test, formulate, manufacture and sell products under the current and/or future medical and recreational cannabis regulations, through subsidiary ADC Biomedical Corp (“BIO”), which is jointly owned by the Algae Dynamics and ARA.
The agreements with Bonify and ARA will help ensure a supply source for cannabis oils to be provided to the University of Waterloo and the University of Western Ontario, pursuant to the Sponsored Research Agreements ADC has in place with the two universities, as previously announced. In addition, the agreements put in place a near-term pathway to revenues by arranging product for export and/or sale to other Licensed Producers. Under the terms of the MOU, Bonify receives a right of first refusal option on cannabis oils processed from plant material supplied to BIO by Bonify.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact email@example.com, or